Contact this trialFirst, we need to learn more about you.
Phosphodiesterase 4 (PDE4) Inhibitor
Long-Term Apremilast Use for Psoriasis
Recruiting2 awardsPhase 3
Edmonton, Alberta
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.